drugset
Drugs / LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
last change Mar 2022 re-read 3 minutes ago

LZRSE-Col7A1 Engineered Autologous Epidermal Sheets

Cell therapy targets COL7A1

Developed for
epidermolysis bullosa dystrophica
Investigated by
Abeona Therapeutics, Inc · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Stanford University

Trials 1

today NCT01263379 · Ph 1/2
20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT01263379 Oct 2010 → Mar 2022 epidermolysis bullosa dystrophica Abeona Therapeutics, Inc Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as LZRSE-Col7A1 Engineered Autologous Epidermal Sheets ClinicalTrials.gov intervention name — accepted as the source's own label NCT01263379 ↗
Modality Cell therapy “gene-corrected autologous cell therapy” PMID 31578311 ↗ Oct 2019
Target COL7A1 “Epidermal sheets were prepared from cells transduced with a retrovirus carrying the full-length human COL7A1 gene.” PMID 31578311 ↗ Oct 2019